EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Development of Candidaemia Score ( CanDi ‐Score) in Decision of Early Empirical Antifungal Treatment for Patients in Intensive Care Unit: The International Prospective Observational ID ‐ IRI Study

Entwicklung des Candidaämie-Scores (CanDi-Score) für die Entscheidung zur frühen empirischen antimykotischen Behandlung bei Patient:innen auf Intensivstationen: internationale prospektive Beobachtungsstudie ID-IRI

Bircan Kayaaslan iD, Halime Araz, Hatice Yağmur Zengin, Rukiyye Bulut iD, Zeynep Oktay, Meltem Tasbakan iD, Sumeyra Istek, Elif Doyuk Kartal, Ozlem Bayrak, Ayse Kaya, Fatma Eser, Pınar Yuruk Atasoy und 31 weitere

Mycoses · 2026-08 · 69 (8)

DOI: 10.1111/myc.70213 ↗

Auf einen Blick

Bei 2.704 ICU-Patient:innen wurde der CanDi-Score zur frühen Vorhersage einer Candidaämie entwickelt. Das Modell zeigte in der Entwicklungsgruppe eine gute Vorhersageleistung (AUC 0,86).

Fragestellung

Welche Risikofaktoren sind bei ICU-Patient:innen mit Candidaämie verbunden, und lässt sich daraus ein praktikabler Vorhersagescore für die frühe empirische antimykotische Behandlung entwickeln?

Methode

Internationale, multizentrische, prospektive Beobachtungsstudie; Erwachsene >18 Jahre mit ICU-Aufenthalt >48 h; Follow-up 30 Tage; Entwicklung und Validierung des CanDi-Scores mit logistischer Regression und Nomogramm.

Ergebnisse

2.704 ICU-Patient:innen, davon 204 mit Candidaämie. Unabhängige Risikofaktoren: höherer CCI, konkurrierende Infektion, Neutropenie, ICU-Aufenthalt >14 Tage, MV >3 Tage, CVC-Dauer und TPN >14 Tage. AUC 0,86 (95 %-KI 0,83–0,88), Sensitivität 79,6 %, Spezifität 76,5 %.

Schlussfolgerung der Autor:innen

Der CanDi-Score kann laut Autor:innen zur frühen Vorhersage und rechtzeitigen empirischen antimykotischen Behandlung bei ICU-Patient:innen mit hohem Risiko dienen.

Kernaussagen

  • 204 von 2.704 ICU-Patient:innen hatten Candidaämie
  • AUC 0,86 (95 %-KI 0,83–0,88) in der Entwicklungsgruppe
  • Risikofaktoren u. a. CCI, Infektion, CVC-Dauer und TPN

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Mycoses, online erschienen am 21.08.2026. Verfasst von Bircan Kayaaslan und 42 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Clinical Microbiology, Ankara Yildirim Beyazit University, Ankara Bilkent City Hospital, Ankara, Türkiye. Hauptthemen laut MEDLINE: Antifungal Agents, Intensive Care Units, Candidemia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Candidaemia remains a common, life‐threatening infection among intensive care unit (ICU) patients, with high mortality, particularly in patients with delayed diagnosis and treatment.

Objectives

This international, multicentre, prospective, observational study aimed to identify risk factors for candidaemia in ICU patients and to develop an easy‐to‐use predictive tool, the CanDi‐Score, for early initiation of empirical antifungal treatment. Patients/Methods All adults over 18 years hospitalised for more than 48 h in the ICUs were included in the study and followed for 30 days. Data on demographics, comorbidities, clinical severity scores including APACHE II and SOFA scores, Charlson comorbidity index (CCI), established risk factors for candidaemia and their time‐dependent effects such as total parenteral nutrition (TPN), mechanical ventilation (MV), and central venous catheter (CVC) were collected. Univariate and multivariate logistic regression analyses were used to identify factors associated with candidaemia development, and fast backwards variable selection was used. To account for between‐centre heterogeneity, sensitivity analyses were performed using mixed‐effects logistic regression models including centre‐specific random intercepts. A nomogram model was constructed using independent risk factors identified in multivariable analysis, and its predictive performance was evaluated with Area Under the Curve (AUC), sensitivity, and specificity.

Results

A total of 2,704 ICU patients, including 204 with candidaemia, were enrolled. Patients with candidaemia had higher APACHE II (19 vs. 13) and CCI scores (6 vs. 5; both p < 0.001), and more frequently had chronic renal failure, haemodialysis, malignancy, recent gastrointestinal surgery, and neutropenia (all p ≤ 0.05). Patients were randomly split into development (80%) and validation (20%) cohorts. Multivariate analysis identified higher CCI, concurrent infection, neutropenia, ICU stay > 14 days, MV > 3 days, CVC duration and TPN > 14 days as independent risk factors. The risk associated with CVC increased substantially with prolonged use (OR: 0–7 days: 3.69; 8–21 days: 8.58; > 21 days: 17.21). The model demonstrated good performance in both the development and validation cohorts, with sensitivity, specificity, and AUC values of 79.6%, 76.5%, and 0.86 (95% CI: 0.83–0.88) in the development cohort, respectively, and comparable predictive performance in the validation cohort. The score model was demonstrated by a nomogram.

Conclusions

Given the high mortality of candidaemia in ICU patients, the CanDi‐Score may serve as a valuable tool for early prediction and timely empirical antifungal treatment. Key predictors include CCI, presence of concurrent infections, the duration of CVC use, and TPN administration. CanDi‐Score provides clinicians with a practical approach to identify high‐risk patients and guides decision‐making for the early initiation of antifungal treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsIntensive Care UnitsCandidemiaHumansProspective StudiesFemaleMiddle AgedRisk FactorsMaleAgedAdultAPACHESeverity of Illness Index

Substanzen

Antifungal Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases and Clinical Microbiology, Ankara Yildirim Beyazit University, Ankara Bilkent City Hospital, Ankara, Türkiye.
  • Department of Infectious Diseases and Clinical Microbiology, Ankara Bilkent City Hospital, Ankara, Türkiye.
  • Department of Biostatistics, Hacettepe University Faculty of Medicine, Ankara, Türkiye.
  • Department of Infectious Diseases and Clinical Microbiology, Necmettin Erbakan University Faculty of Medicine, Konya, Türkiye.
  • Department of Infectious Diseases and Clinical Microbiology, Ege University Faculty of Medicine, Izmir, Türkiye.
  • Department of Infectious Diseases and Clinical Microbiology, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Türkiye.

ORCID-Profile: Bircan Kayaaslan, Rukiyye Bulut, Meltem Tasbakan, Mustafa Uguz, Sema Sarı, Bahar Busra Sivrikaya, Ilad Alavi Darazam, Mohammad Mehdi Shadravan, Ahmet Cem Yardımcı, Zeynep Ture

Zitieren

APA

Kayaaslan, B., Araz, H., Zengin, H. Y., Bulut, R., Oktay, Z., Tasbakan, M., Istek, S., Kartal, E. D., Bayrak, O., Kaya, A., Eser, F., Atasoy, P. Y., Kıratlı, H. E., Doruk, B. C., Uguz, M., Sarı, S., Sivrikaya, B. B., Akkoyunlu, Y., Altunal, L. N., …, & Erdem, H. (2026). Development of Candidaemia Score ( CanDi ‐Score) in Decision of Early Empirical Antifungal Treatment for Patients in Intensive Care Unit: The International Prospective Observational ID ‐ IRI Study. Mycoses, 69(8). https://doi.org/10.1111/myc.70213

Vancouver

Kayaaslan B, Araz H, Zengin HY, Bulut R, Oktay Z, Tasbakan M, et al. Development of Candidaemia Score ( CanDi ‐Score) in Decision of Early Empirical Antifungal Treatment for Patients in Intensive Care Unit: The International Prospective Observational ID ‐ IRI Study. Mycoses. 2026;69(8). doi:10.1111/myc.70213

BibTeX
@article{Kayaaslan2026,
  author = {Kayaaslan, Bircan and Araz, Halime and Zengin, Hatice Yağmur and Bulut, Rukiyye and Oktay, Zeynep and Tasbakan, Meltem and Istek, Sumeyra and Kartal, Elif Doyuk and Bayrak, Ozlem and Kaya, Ayse and Eser, Fatma and Atasoy, Pınar Yuruk and Kıratlı, Hatice Esranur and Doruk, Berfin Cirkin and Uguz, Mustafa and Sarı, Sema and Sivrikaya, Bahar Busra and Akkoyunlu, Yasemin and Altunal, Lutfiye Nilsun and Albayrak, Ayse and Alay, Handan and Iskender, Gulsen and Amani, Elkholy and Onder, Taylan and Ozcengiz, Dilek and Turktan, Mediha and Mirko, Mihalj and Darazam, Ilad Alavi and Shadravan, Mohammad Mehdi and Sahzabi, Reza Yahyavi and Yardımcı, Ahmet Cem and Korkmazer, Ruveyda and Senol, Gunes and Kuruoglu, Tuba and Temocin, Fatih and Alıcı, Ozlem and Sonmezoglu, Meral and Esmaoglu, Aliye and Ture, Zeynep and Cortegiani, Andrea and Akyıldız, Ozay and Guner, Hatice Rahmet and Erdem, Hakan},
  title = {Development of Candidaemia Score ( CanDi ‐Score) in Decision of Early Empirical Antifungal Treatment for Patients in Intensive Care Unit: The International Prospective Observational ID ‐ IRI Study},
  journal = {Mycoses},
  year = {2026},
  volume = {69},
  number = {8},
  doi = {10.1111/myc.70213}
}
Kostenlos starten →